NGNE
MaterialsNeoleukin Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving NGNE Today?
No stock-specific AI insight has been generated for NGNE yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
NGNE News
20 articles- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 6, 2026
- We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business GrowthYahoo Finance·May 5, 2026
- Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene TherapyYahoo Finance·Apr 28, 2026
- Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of DirectorsYahoo Finance·Apr 20, 2026
- Neurogene: Q4 Earnings SnapshotYahoo Finance·Mar 24, 2026
- Neurogene Reports Full Year 2025 Financial Results and Highlights Recent UpdatesYahoo Finance·Mar 24, 2026
- Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at ConferenceMarketbeat·Mar 21, 2026
- Neurogene to Participate in Stifel 2026 Virtual CNS ForumYahoo Finance·Mar 11, 2026
- Block upgraded, Duolingo downgraded: Wall Street's top analyst callsYahoo Finance·Feb 27, 2026
- Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More247 Wall St·Feb 27, 2026
- Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett SyndromeYahoo Finance·Feb 26, 2026
- Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim SummitMarketbeat·Feb 14, 2026
- Neurogene to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 5, 2026
- Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Feb 4, 2026
- Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett SyndromeYahoo Finance·Jan 12, 2026
- Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 5, 2026
- Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In GrowthYahoo Finance·Nov 26, 2025
- Neurogene: Q3 Earnings SnapshotYahoo Finance·Nov 13, 2025
- Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent UpdatesYahoo Finance·Nov 13, 2025
- Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett SyndromeYahoo Finance·Nov 12, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Neoleukin Therapeutics Inc
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.